Between Jan 14, 2019, and Jun 18, 2021, 96 patients (pts) were enrolled and 13 pts were excluded due to inclusion violations. At data cutoff (Feb 24, 2022), 83 pts. (demographics are shown in Table 1) were available for efficacy and safety analysis...Confirmed ORR was 30.4% (95% confidence interval [CI]: 13.2, 52.9), with all seven patients achieving partial response. DCR was 78.3% (95% CI: 56.3, 92.5), median PFS was 5.4 months (95% CI: 2.8, 8.6), and median OS was not reached (95% CI: 6.7, not estimable).Sitravatinib plus tislelizumab demonstrated a manageable safety and tolerability profile as well as antitumor activity in patients with PD-L1+, locally advanced or metastatic squamous NSCLC who had not received prior systemic treatment in the metastatic setting.